文献速递治疗药物监测与药物基因组学药物相互作用

英国基层医疗实施预emptive药物基因组学检测的潜在影响评估

Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK.
PubMed 文献 · Br J Clin Pharmacol · 2021-01-19

本研究基于2019年英国大型社区药房数据库,估算56种常用药物首次处方的全国发生率,并结合表型频率数据估算可操作药物-基因相互作用的发生情况。结果显示19.1%–21.1%的新处方存在可操作DGI,其中8.6%–9.1%需立即调整剂量或方案。

要点

  • 英国基层医疗中可操作药物-基因相互作用频繁发生,存在优化处方的较大空间
  • 约19.1%–21.1%的56种药物新处方存在可操作DGI
  • 8.6%–9.1%的新处方需立即调整剂量或更换药物方案

核心结论

  • 在英国基层医疗中,可操作药物-基因相互作用频繁发生,存在优化处方的较大机会。

主要发现

  • 56种药物的全部新处方(每年27 411 288张)中,19.1%–21.1%(n=5 233 353–5 780 595)存在可操作DGI。
  • 可操作DGI可导致增加监测、防范最大剂量上限或可选/立即的药物或剂量调整。
  • 立即剂量调整或更换药物方案占这些处方的8.6%–9.1%(n=2 354 058–2 500 283)。

关键数值与推荐

  • 可操作DGI依据荷兰药物基因组学工作组和/或临床药物基因组学实施联盟指南判定。
  • 19.1%–21.1%(n=5 233 353–5 780 595)的新处方存在可操作DGI。
  • 8.6%–9.1%(n=2 354 058–2 500 283)的新处方需立即调整剂量或更换方案。

临床怎么用

  • 在基层医疗处方前考虑常见基因变异对9个相关基因对应药物的影响,识别需增加监测、限制最大剂量或调整方案的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Pharmacogenetics (PGx) in the UK is currently implemented in secondary care for a small group of high-risk medicines. However, most prescribing takes place in primary care, with a large group of medicines influenced by commonly occurring genetic variations. The goal of this study is to quantitatively estimate the volumes of medicines impacted by implementation of a population-level, pre-emptive pharmacogenetic screening programme for nine genes related to medicines frequently dispensed in primary care in 2019. METHODS: A large community pharmacy database was analysed to estimate the national incidence of first prescriptions for 56 PGx drugs used in the UK for the period 1 January-31 December 2019. These estimated prescription volumes were combined with phenotype frequency data to estimate the occurrence of actionable drug-gene interactions (DGI) in daily practice in community pharmacies. RESULTS: In between 19.1 and 21.1% (n = 5 233 353-5 780 595) of all new prescriptions for 56 drugs (n = 27 411 288 new prescriptions/year), an actionable drug-gene interaction (DGI) was present according to the guidelines of the Dutch Pharmacogenetics Working Group and/or the Clinical Pharmacogenetics Implementation Consortium. In these cases, the DGI would result in either increased monitoring, guarding against a maximum ceiling dose or an optional or immediate drug/dose change. An immediate dose adjustment or change in drug regimen accounted for 8.6-9.1% (n = 2 354 058-2 500 283) of these prescriptions. CONCLUSIONS: Actionable drug-gene interactions frequently occur in UK primary care, with a large opportunity to optimise prescribing.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Youssef E, Kirkdale CL, Wright DJ, et al. Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK. Br J Clin Pharmacol. 2021. PMID: 33464647. doi:10.1111/bcp.14704

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。